Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by QT Interval Prolongation Experts (US)

Eric Gruff, PhD MBA, Principal
Eric Gruff, PhD MBA, Principal
E4 Consulting
Analysis of: Burden of diabetes care rivals disease complications (www.reuters.com)
A recent Chicago-area study has made it clear that diabetics view the daily-injection routine as being equally as onerous as many of the long-term complications from the uncontrolled disease. In addition to multiple daily injections, diabetic patients usually take several concommitant medications every...
Analysis of: Galvus(R) receives European approval as new treatment for type 2 diabetes with broad range of indications (www.pipelinereview.com)
The approval of Galvus in Europe increases the pressure on the FDA to approve its use in the United Status.
Analysis of: FDA Holds Off on Approving A Proposed Migraine Drug (online.wsj.com)
FDA requirements for and evaluations of genetic toxicology testing can have important consequences for FDA and EU approval of pharmaceutical products.  This is true throughout the drug discovery and drug development processes -- from prePhase I through NDA approval, as shown by the drop in stock...
Eric Gruff, PhD MBA, Principal
Eric Gruff, PhD MBA, Principal
E4 Consulting
Analysis of: Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients (www.pipelinereview.com)
The results of two Phase III trials conducted by Novo Nordisk on liraglutide, a once-daily dosed GLP-1 analog, indicate significant glucose lowering efficacy and weight loss. On a positive note, Novo has to be relieved that they are seeing the same magnitude of HbA1c reduction and weight loss...
Analysis of: Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds (boston.stockgroup.com)
Factor IX is also a promising target, as it is unique in carrying the coagulation signal from the site of injury with tissue factor activation, to the surface of platelets, where propagation and amplification of coagulation actually occur. REG1 (Regado Biosciences), a highly specific, actively reversible...
Richard Anthony, PhD, Board member
Richard Anthony, PhD, Board member
Janus Pharmaceuticals, Inc.
Analysis of: Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynaud's Disease (www.pipelinereview.com)
Viagra (sildenafil) a same a PDE-5 same  class compound as SLx-2101 has shown efficacy for Raynaud's by significantly reducing the frequency and duration of Raynaud attacks and improved capillary flow velocity by 400%, according to a study led by Roland Fries, M.D and published online...
Analysis of: Over-The-Counter Weight Loss Drug Approved (abclocal.go.com)
does it work?  Is the AE profile translatable to a larger population? 
Analysis of: Vegf Trap-Eye Phase 2 Wet Amd Results Reported At Arvo Annual Meeting (www.pipelinereview.com)
VEGF Trap could be better than Lucentis or Avastin in that it can neutralize VEGF isoforms that Lucentis or Avastin cannot neutralize.
May 18, 2007
AMD Treatments
Analysis of: Ranibizumab, PDT combination successfully treats neovascular AMD (www.osnsupersite.com)
Ranibizumab and PDT are both approved treatments and hence are interesting to see how they compare in combination. 
April 30, 2007
not yet
Analysis of: Major phase 3 program planned for new antiplatelet drug (www.theheart.org)
The only available oral inhibitor of thrombin is warfarin which is a nightmare compound to deal with from a level and DDI standpoint.   

Previous Page : 1 2 3 4 5 Next31 to 40 of 42

Analytics


Generated at 2009-01-09T13:00:20.343